Day: March 22, 2025
Annual Report 2024Regulated information 22 March 2025
The board of directors of Financière de Tubize has established the 2024 annual report. This report is available on the website www.financiere-tubize.beProfit for the financial year: € 90.1 million (€ 88.2 million in 2023, + 2,2%),
Reduction of outstanding bank borrowings from € 79.2 million at 31 December 2023 to € 41.3 million at 31 December 2024,
Acquisition, in 2024, of 53,706 UCB shares, increasing the holding of the Company in UCB from 36.24% on 31 December 2023 to 36.27% on 31 December 2024.If the general shareholders meeting of 25 April 2025 approves the 2024 annual accounts, including the proposed result appropriation, a gross dividend of € 1.04 (compared to €0.97 for financial year 2023, an increase of 7.2%) will be payable as from 5 May 2025 onwards at the offices, seats...
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Written by Customer Service on . Posted in Public Companies.
Company AnnouncementAbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)
Genmab categorically refutes allegations and will vigorously defend the companyCOPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today thatAbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and former AbbVie employees as defendants. AbbVie alleges that the defendants have misappropriated AbbVie’s alleged trade secrets relating to the use of disaccharides to improve the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs) in connection with rinatabart sesutecan (Rina-S™) and other ADC pipeline products of ProfoundBio....